CytomX's core business segment revolves around the research, development, and clinical advancement of novel oncology therapeutics. This involves leveraging the company's proprietary Probody platform to create conditionally activated antibodies and antibody-drug conjugates (ADCs) that target tumor-specific microenvironments. R&D activities encompass target identification, antibody engineering, preclinical studies, and clinical trials across various cancer types. The focus is on enhancing efficacy and reducing systemic toxicity by ensuring that the therapeutic payload is activated primarily within the tumor. This segment addresses unmet needs in cancer treatment by developing safer and more effective therapies, potentially improving patient outcomes and quality of life. Strategic partnerships with pharmaceutical companies like AbbVie, Amgen, and Bristol-Myers Squibb are crucial for expanding the pipeline and accelerating drug development.

The Probody technology platform is a key business segment, representing CytomX's innovative approach to developing conditionally activated biologics. This platform is designed to create masked antibodies that are inert in circulation but become activated in the tumor microenvironment, reducing off-target effects and improving therapeutic index. Research and development efforts within this segment focus on optimizing the Probody design, enhancing protease sensitivity, and expanding the platform's applicability to various therapeutic modalities, including ADCs and T-cell engagers. The platform's success is measured by its ability to generate clinical candidates with improved safety profiles and enhanced efficacy. Future opportunities include exploring new activation mechanisms, expanding the platform to address other disease areas beyond oncology, and out-licensing the technology to other companies.